4-Ethyl-2,6-difluoroaniline | 1452007-17-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Ethyl-2,6-difluoroaniline
• CAS: 1452007-17-8
• 化学式: C₈H₉F₂N
• 分子量: 157.163
• InChiKey: CWOOIKWKZRRDKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]benzonitrile 、 4-Ethyl-2,6-difluoroaniline 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 4-((4-chloro-6-((4-ethyl-2,6-fluorophenyl)amino)-1,3,5-triazin-2-yl)amino)benzonitrile
  参考文献：
  名称：

  Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility

  摘要：

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high anti-viral activity. The solubility enhancements come from strategic placement of a morpholinylalkoxy substituent in the entrance channel of the NNRTI binding site. Compound 4d shows low-nanomolar activity similar to etravirine towards wild-type HIV-1 and key viral variants. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.091

文献信息

• BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119
  申请人：Xia Yan

  公开号：US20110212938A1

  公开（公告）日：2011-09-01

  The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

  本发明涉及双环杂环衍生物、包含双环杂环衍生物的组合物以及使用双环杂环衍生物治疗或预防患者的肥胖症、糖尿病、代谢紊乱、心血管疾病或与GPR119活性相关的疾病的方法。
• Antibacterial compounds
  申请人：Redx Pharma PLC

  公开号：US10385065B2

  公开（公告）日：2019-08-20

  The invention relates to antibacterial and anti-mycobacterial drug compounds of formula I. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the derivatives in treating bacterial infections, and methods of treating bacterial infections. The invention is also directed to antibacterial drug compounds capable of treating bacterial infections that are currently hard to treat with existing drug compounds, e.g., those caused by resistant bacterial or mycobacterial strains.

  本发明涉及式 I 的抗菌和抗霉菌药物化合物，还涉及抗菌药物化合物的药物制剂。 本发明还涉及这些衍生物在治疗细菌感染中的用途，以及治疗细菌感染的方法。 本发明还涉及能够治疗目前难以用现有药物化合物治疗的细菌感染的抗菌药物化合物，例如由抗药性细菌或分枝杆菌菌株引起的细菌感染。
• ANTIBACTERIAL COMPOUNDS
  申请人：REDX PHARMA PLC

  公开号：US20170158708A1

  公开（公告）日：2017-06-08

  The invention relates to antibacterial and anti-mycobacterial drug compounds of formula I. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the derivatives in treating bacterial infections, and methods of treating bacterial infections. The invention is also directed to antibacterial drug compounds capable of treating bacterial infections that are currently hard to treat with existing drug compounds, e.g., those caused by resistant bacterial or mycobacterial strains.
• PHOTOAFFINITY PROBES
  申请人：Promega Corporation

  公开号：US20200340982A1

  公开（公告）日：2020-10-29

  Provided herein are compositions and methods for photoaffinity labeling of molecular targets. In particular, probes that specifically interact with cellular targets based on their affinity and are then covalently linked to the cellular target via a photoreactive group (PRG) on the probe.
• US8907095B2
  申请人：——

  公开号：US8907095B2

  公开（公告）日：2014-12-09